[New therapies against HCV].

Autor: Kin N; Unité de Recherche Risques Microbiens (EA4655), Université de Caen Normandie, Esplanade de la Paix, F-14000 Caen., Vabret A; Laboratoire de virologie, CHU Caen, Avenue Georges Clemenceau, F-14000 Caen.
Jazyk: francouzština
Zdroj: Revue francophone des laboratoires : RFL [Rev Francoph Lab] 2016 Dec; Vol. 2016 (487), pp. 25-33. Date of Electronic Publication: 2016 Dec 26.
DOI: 10.1016/S1773-035X(16)30369-0
Abstrakt: Human coronaviruses (HCoV) are single strand RNA viruses. To date, there are four so-called « classical » or « novel » HCoVs, characterized by a winter circulation. These coronaviruses are responsible for mild respiratory infection in general population. However, HCoVs are associated to more severe respiratory tract infection among susceptible population. Indeed, HCoVs account for 2 to 7% of hospitalizations due to a respiratory infection, particularly among children, immunocompromised or elderly people. Thereby, HCoVs are included in the panel of respiratory viruses detected in routine using molecular biology tools. These four circulating HCoVs have to be distinguished from the two emerging HCoVs: SARS-CoV and MERS-CoV. These later are associated to a more severe respiratory infection and differ from other HCoVs by their increased epidemic potential, their more important health impact, and their atypical circulation. Such as paramyxoviruses and Influenza viruses, coronaviruses have to be monitored due to their associated risk of emergence in human population from animal reservoirs.
(Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: